Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure

Circulation

Volumn 110, Issue 8, 2004, Pages 1006-1012

  Bahlmann, Ferdinand H ^a,b   Song, Rong ^a   Boehm, Sascha M ^a   Mengel, Michael ^b   Von Wasielewski, Reinhard ^b   Lindschau, Carsten ^a   Kirsch, Torsten ^a   De Groot, Kirsten ^a   Laudeley, Robert ^c   Niemczyk, Eva ^c   Güler, Faikah ^a   Menne, Jan ^c   Haller, Hermann ^a   Fliser, Danilo ^a  

^a Division of Nephrology and Hypertension   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c Phenos GmbH   (Germany)

Author keywords

Apoptosis; Endothelium; Erythropoietin; Tissue; Vasculature

Indexed keywords

ERYTHROPOIETIN; MITOGEN ACTIVATED PROTEIN KINASE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PROTECTIVE AGENT; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERIOSCLEROSIS; ARTICLE; BLOOD PRESSURE; CELL PROTECTION; CELL STIMULATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVATION; GLOMERULOSCLEROSIS; HEMATOCRIT; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY ISCHEMIA; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RAT; RENOVASCULAR DISEASE; SIGNAL TRANSDUCTION; SURVIVAL;

ANIMALS; APOPTOSIS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; ENDOTHELIUM, VASCULAR; ERYTHROPOIETIN; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HEMATOCRIT; HEMATOPOIETIC STEM CELL MOBILIZATION; HYPERTENSION, RENAL; ISCHEMIA; KIDNEY; LIFE TABLES; MALE; MULTIPLE ORGAN FAILURE; NEPHRECTOMY; NEPHRITIS, INTERSTITIAL; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION;

EID: 4344626952     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000139335.04152.F3     Document Type: Article

References (29)

1. Kang DH, Kanellis J, Hugo C, et al. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol. 2002;13:806-816.
2. El Nahas M. Kidney remodelling and scarring: the plasticity of cells. Nephrol Dial Transplant. 2003;18:1959-1962.
3. Kang DH, Hughes J, Mazzali M, et al. Impaired angiogenesis in the remnant kidney model, II: vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol. 2001;12:1448-1457.
4. Ostendorf T, Kunter U, Eitner F, et al. VEGF(165) mediates glomerular endothelial repair. J Clin Invest. 1999;104:913-923.
5. Lappin TR, Maxwell AP, Johnston PG. EPO's alter ego: erythropoietin has multiple actions. Stem Cells. 2002;20:485-492.
6. Sasaki R, Masuda S, Nagao M. Pleiotropic functions and tissue-specific expression of erythropoietin. News Physiol Sci. 2001;16:110-113.
7. Goldman SA, Nedergaard M. Erythropoietin strikes a new cord. Nat Med. 2002;8:785-787.
8. Juul SE, Yachnis AT, Christensen RD. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev. 1998;52:235-249.
9. Morishita E, Masuda S, Nagao M, et al. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience. 1997;76:105-116.
10. Sakanaka M, Wen TC, Matsuda S, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA. 1998;95:4635-4640.
11. Celik M, Gokmen N, Erbayraktar S, et al. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci USA. 2002;99:2258-2263.
12. Carlini RG, Dusso AS, Obialo CI, et al. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int. 1993;43:1010-1014.
13. Anagnostou A, Lee ES, Kessimian N, et al. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA. 1990;87:5978-5982.
14. Ribatti D, Presta M, Vacca A, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood. 1999;93:2627-2636.
15. Carlini RG, Reyes AA, Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int. 1995;47:740-745.
16. Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Aktl and mitochondrial modulation of cysteine proteases. Circulation. 2002;106:2973-2979.
17. Parsa CJ, Matsumoto A, Kim J, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest. 2003;112:999-1007.
18. Bahlmann FH, De Groot K, Spandau JM, et al. Erythropoietin regulates endothelial progenitor cells. Blood. 2004;103:921-926.
19. Garcia DL, Anderson S, Rennke HG, et al. Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. Proc Natl Acad Sci U S A. 1988;85:6142-6146.
20. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584-590.
21. Calvillo L, Latini R, Kajstura J, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A. 2003;100:4802-4806.
22. Haller H, Christel C, Dannenberg L, et al. Signal transduction of erythropoietin in endothelial cells. Kidney Int. 1996;50:481-488.
23. Heeschen C, Aicher A, Lehmann R, et al. Erythropoietin is a potent physiological stimulus for endothelial progenitor cell mobilization. Blood. 2003;102:1340-1346.
24. Cerami A, Brines M, Ghezzi P, et al. Neuroprotective properties of epoetin alfa. Nephrol Dial Transplant. 2002;17(suppl 1):8-12.
25. Bahlmann FH, Degroot K, Duckert T, et al. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int. 2003;64:1648-1652.
26. Dimmeler S, Zeiher AM. Akt takes center stage in angiogenesis signaling. Circ Res. 2000;86:4-5.
27. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6:1004-1010.
28. Shiojima I, Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res. 2002;90:1243-1250.
29. Mangi AA, Noiseux N, Kong D, et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med. 2003;9:1195-1201.